When was ZEO ScientifiX founded?

ZEO ScientifiX was founded in 2011 and raised its 1st funding round 13 years after it was founded.

Where is ZEO ScientifiX located?

ZEO ScientifiX is headquartered in Fort Lauderdale, United States.

How many employees does ZEO ScientifiX have?

As of Sep 30, 2026, the latest employee count at ZEO ScientifiX is 32.

Is ZEO ScientifiX a funded company?

ZEO ScientifiX is a funded company, having raised a total of $1M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jul 08, 2024.

When was the latest funding round of ZEO ScientifiX?

ZEO ScientifiX's latest funding was a $***** Seed round on Nov 30, 2025, with participation from 0 investor. Its primary sector is Orthopedics. In United States, the Orthopedics sector has seen $2.64B in funding in 2026 to date.

What is the annual revenue of ZEO ScientifiX?

Annual revenue of ZEO ScientifiX is between $1M and $10M as on Oct 31, 2025

Where does ZEO ScientifiX rank among its competitors?

ZEO ScientifiX ranks 11th amongst 107 active competitors, of which 35 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Remedium Bio, which secured $10M in Aug, 2026.

Who are the top competitors of ZEO ScientifiX?

ZEO ScientifiX's top competitors include Theravance Biopharma, Eupraxia Pharmaceuticals and Retro. Among them, Remedium Bio secured the most recent funding round in August, 2026.

ZEO ScientifiX - 2026 Company Profile, Funding, Competitors & Financials

ZEO ScientifiX is a seed company based in Fort Lauderdale (United States), founded in 2011. It operates as a Biopharmaceutical company focused on researching novel biological therapeutics. ZEO ScientifiX has raised $1M in funding. The company has 107 active competitors, including 35 funded and 13 that have exited. Its top competitors include companies like Theravance Biopharma, Eupraxia Pharmaceuticals and Retro.

Company Details

Biopharmaceutical company focused on researching novel biological therapeutics. The company offer Patient Pure X a concentrated autologous exosome product that contains highly bioactive nanoparticle to decrease inflammation and promote tissue healing. It also provide therapeutics that contain concentrated nanoparticles containing small RNAs called micro RNA, lipids, enzymes, and bioactive growth factors and proteins for regenerative and anti-aging aesthetic results.

Website: www.zeoscientifix.com/
Social
Email ID: *****@zeoscientifix.com
Phone Number: +1 **********

Key Metrics

Founded Year

2011

Location

Fort Lauderdale, United States

Stage

Seed

Total Funding

$1M in 2 rounds

Latest Funding Round

Seed, Nov 30, 2025, $*****

Ranked

11^th among 107 active competitors

Annual Revenue

$1M - $10M as on Oct 31, 2025

Employee Count

32 as on Sep 30, 2026

Similar Companies

Theravance Biopharma & 112 more

View ZEO ScientifiX's full profile

ZEO ScientifiX is associated with 3 legal entities given below:

Legal Entity Name	Revenue	Latest Employee Count	Reports
Zeo Scientifix, Inc. CIN: 1557376 , United States, Active	$1M - $10M (As on Oct 31, 2025)	-	-
Organicell Regenerative Medicine, Inc. CIN: 1557376 , United States, Active	$5M - $25M (As on Aug 25, 2023)	-	-
BIOTECH PRODUCTS SERVICES & RESEARCH, INC. CIN: 1557376 , United States, Active	$1M - $10M (As on Oct 31, 2023)	-	-

ZEO ScientifiX has raised a total funding of $1M over 2 rounds. Its first funding round was on Jul 08, 2024.

Here is the list of recent funding rounds of ZEO ScientifiX:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 30, 2025	7628025	Seed	7946413	2970962	1923061	2217581
Jul 08, 2024	4901057	Seed	1591569	8680174	4820044	6426797

Access funding benchmarks and valuations. Sign up today!

View details of ZEO ScientifiX's funding rounds and investors

ZEO ScientifiX's employee count trend

ZEO ScientifiX has 32 employees as of Sep 26. Here is ZEO ScientifiX's employee count trend over the years:

Uncover ZEO ScientifiX's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ZEO ScientifiX include Theravance Biopharma, Eupraxia Pharmaceuticals and Retro. Here is the list of Top 10 competitors of ZEO ScientifiX, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Theravance Biopharma 2001, Francisco (United States), Public	Developer of therapeutics for inflammatory and immunological diseases	-	Sierra Ventures, Acorn Bioventures & 6 others	64/100
2nd	Eupraxia Pharmaceuticals 2012, Vancouver (Canada), Public	Sustained released formulation for osteoarthritis	$2.44M	SVB, National Research Council Canada & 2 others	62/100
3rd	Retro 2020, Redwood City (United States), Series A	Developer of therapeutics targeting cellular mechanisms to treat aging diseases	$180M	4P CAPITAL & 1 others	61/100
4th	MediciNova 2000, San Diego (United States), Public	Developer of small molecule for the treatment of acute exacerbations of asthma and COPD	$83.9M	JAFCO Group, Aspire Capital & 15 others	59/100
5th	TissueGene 1999, Rockville (United States), Series C	Developer of regenerative therapies for orthopedic diseases	$94.6M	Q Capital Partners, Maryland Stem Cell Research Fund ... Read more	58/100
6th	Remedium Bio 2020, Needham (United States), Series A	Developer of gene therapies for a broad range of diseases	$15M	LifeSpan Vision Ventures, https://hkxcapital.com ... & 10 others	57/100
7th	Expedition Therapeutics 2024, San Francisco (United States), Series B	Developer of treatments targeting inflammatory and respiratory diseases for patient care	$280M	General Atlantic, Novo Holdings & 12 others	56/100
8th	Levicept 2012, Sandwich (United Kingdom), Series B	Developer of therapeutics for the treatment of chronic pain	$50.9M	Pfizerpro, Gilde Healthcare & 8 others	56/100
9th	Immunis 2018, Irvine (United States), Series A	Developer of cell therapies for age-related and disease-related immune deficits	$67.4M	Remiges Ventures, Bold Capital Partners & 4 others	56/100
10th	Altesa Biosciences 2020, College Park (United States), Series B	Developer of drugs to treat RNA viruses	$110M	Forbion, Atlantic Partners & 4 others	54/100
11th	ZEO ScientifiX 2011, Fort Lauderdale (United States), Seed	Biopharmaceutical company focused on researching novel biological therapeutics	$1M	-	52/100